Hepatocellular Carcinoma Presenting as an Incidental Isolated Malignant Portal Vein Thrombosis

Poddar, Nishant; Avezbakiyev, Boris; He, Zili; Jiang, Meijie; Gohari, Arash; Wang, Jen Chen

doi:10.1007/s12029-010-9235-z

Cited by 19 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, PVTT is present in 44% of patients with HCC according to autopsy data and in 31–34% according to clinical data [2]. PVTT can cause partial or total portal vein occlusion and extensive intra- or extrahepatic metastases [3]. Moreover, PVTT in the main portal trunk puts pressure on the portal vein, which would further lead to gastrointestinal bleeding and ascites and induce multiple intrahepatic tumor dissemination and recurrence.…”

Section: Introductionmentioning

confidence: 99%

“…The median survival of patients with HCC and PVTT is 2.7–4.0 months, whereas survival in patients with HCC but without PVTT is 24.4 months [5–7]. For these patients, there is no effective treatment and the optimal treatment remains controversial [3]. Most HCCs with PVTT are technically unresectable and they are not suitable for curative therapies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus

Sun

Zhou

Zhu

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

Aim was to assess the therapeutic value of portal vein stenting (PVS) combined with iodine-125 seed (125I seed) strand endovascular implantation followed by transcatheter arterial chemoembolization (TACE) for treating patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). This was a retrospective study of 34 patients aged 29–81 years, diagnosed HCC with PVTT, and treated with PVS combined with 125I seed strand endovascular implantation followed by TACE between January 2012 and August 2014. Survival, stent patency, technical success rate, complications related to the procedure, and adverse events were recorded. The technical success rate was 100%. No serious procedure-related adverse event was recorded. The median survival was 147 days. The cumulative survival rates and stent patency rates at 90, 180, and 360 days were 94.1%, 61.8%, and 32.4% and 97.1% (33/34), 76.9% (24/34), and 29.4% (10/34), respectively. PVS combined with 125I seed strand endovascular implantation followed by TACE is feasible for patients with HCC and PVTT. It resulted in appropriate survival and stent patency, with no procedure-related adverse effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus

Sun

Zhou

Zhu

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…A few case reports have described SVT as the first sign of liver and pancreatic malignancies. [7][8][9] A meta-analysis of 32 studies, each including between 10 and 237 patients with portal or hepatic vein thrombosis (HVT), showed that thrombosis often occurred prior to diagnosis of myeloproliferative neoplasms. 10 The association between SVT and subsequent cancer risk has never been studied in a population-based setting using a comparison cohort.…”

Section: Introductionmentioning

confidence: 99%

Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival

Søgaard

Farkas

Pedersen

et al. 2015

Blood

View full text Add to dashboard Cite

Key Points• SVT is a marker of occult cancer, in particular myeloproliferative neoplasms, liver cancer, and pancreatic cancer.• SVT is a prognostic factor for short-term survival in patients diagnosed with liver or pancreatic cancer.It is unknown if splanchnic venous thrombosis (SVT) is a marker of occult cancer and a prognostic factor for cancer survival. Using Danish medical registries, we conducted a nationwide cohort study including all patients with first-time SVT (n 5 1191) between 1994 and 2011. We followed the patients for subsequent cancer diagnoses and calculated absolute risks and standardized incidence ratios (SIRs). We formed a matched comparison cohort of cancer patients without SVT, and assessed the prognostic impact of SVT on cancer survival by applying the Kaplan-Meier method and Cox regression. We followed the patients for a median of 1.6 years, and found that SVT was a marker of occult cancer. The 3-month cancer risk was 8.0% and the SIR was 33 (95% confidence interval, 27-40), compared with the general population. Increased risk was mainly found for liver cancer (risk 5 3.5%; SIR 5 1805), pancreatic cancer (risk 5 1.5%; SIR 5 256), and myeloproliferative neoplasms (risk 5 0.7%; SIR 5 764). The overall SIR remained increased twofold after 1 or more years of follow-up. SVT was also a prognostic factor for survival in patients with liver and pancreatic cancer. The clinical impact may be a more thorough diagnostic work-up in patients presenting with SVT. (Blood. 2015;126(8):957-963)

show abstract

“…Одной из основных локальных причин развития тромбозов в висцеральном венозном бассейне (от 4 до 16%) являются онкологические заболевания органов брюшной полости, при этом венозный тромбоз служит, как правило, его первым признаком [30,73]. В ряде работ именно на тромбоз висцеральных вен указывают как на первое проявление гепатоцеллюлярного рака и рака поджелудочной железы [51,59,62,66,76].…”

Section: этиологияunclassified

Venous acute disturbance of mesenteric circulation: diagnosis and treatment

Хрипун

Шурыгин

Миронков

et al. 2017

Khir. Z. im. N.I. Pirogova

View full text Add to dashboard Cite

Кафедра хирургии и эндоскопии (зав.-д.м.н., проф. А.И. Хрипун) факультета дополнительного профессионального образования Российского национально-исследовательского медицинского университета им. Н.И. Пирогова; 2 ГБУЗ «Городская клиническая больница им. В.М. Буянова» (главный врач-к.м.н. А.В. Саликов) Департамента здравоохранения Москвы, Москва, Россия Ключевые слова: острое нарушение мезентериального кровообращения, диагностика, лечение.

show abstract

Hepatocellular Carcinoma Presenting as an Incidental Isolated Malignant Portal Vein Thrombosis

Cited by 19 publications

References 20 publications

Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus

Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus

Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival

Venous acute disturbance of mesenteric circulation: diagnosis and treatment

Contact Info

Product

Resources

About